Investigating how to improve bone health by targeting a specific cellular pathway affected by parathyroid hormone.
Targeting the ubiquitin-proteasome pathway to reverse catabolic action of PTH in bone
This study is looking at how a hormone called parathyroid hormone affects bone health and how different treatments can either help build bone or cause it to weaken, with the goal of finding better ways to help people with bone diseases.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Thomas Jefferson University NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10873971 on NIH RePORTER |
What this research studies
This research focuses on understanding how parathyroid hormone (PTH) affects bone metabolism, particularly how different treatment regimens can lead to either bone formation or bone loss. The study examines the role of the ubiquitin-proteasome pathway in regulating the effects of PTH on bone cells, specifically looking at how continuous PTH treatment can lead to negative outcomes. By using a proteasome inhibitor called ixazomib, the researchers aim to block the adverse effects of continuous PTH treatment and enhance its beneficial actions on bone health. This could lead to improved therapies for patients with metabolic bone diseases.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with metabolic bone diseases who are undergoing treatment with parathyroid hormone.
Not a fit: Patients who do not have metabolic bone diseases or those who are not receiving PTH therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for improving bone health and preventing bone loss in patients receiving PTH therapy.
How similar studies have performed: Previous research has shown promising results in targeting the ubiquitin-proteasome pathway for improving bone health, indicating that this approach has potential for success.
Where this research is happening
Philadelphia, United States
- Thomas Jefferson University — Philadelphia, United States (Active)
Researchers
- Principal investigator: Wang, Bin — Thomas Jefferson University
- Study coordinator: Wang, Bin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.